Trading Sections

Iren Ltd.: JPMorgan Sees a Price Target of $65 and the Nvidia Alliance Shapes the Market!

JPMorgan upgrades Iren Ltd. (IREN) to "Overweight" and sees a price target of $65. The business model...

Pyxis Oncology: Wells Fargo Sees 2 Billion USD Peak Revenue for New Cancer Drug MICVO

Wells Fargo raises the price target for Pyxis Oncology (PYXS) to 19 USD based on recent study data,...

Lithium Americas Corp.: The 1.6 Billion USD Investment Aimed at Securing America's Supply Chains - Experts See 100% Price Potential

JPMorgan sees a 100% upside potential due to raised lithium price assumptions and sets the price target...

Climb Bio: How a modified antibody could change the market for kidney diseases

Climb Bio (CLYM) focuses on its lead product CLYM116 aimed at the addressable market for IgA Nephropathy...

Alibaba: Specific Payback Cycles and a $175 Price Target Bring AI Cloud into Focus

Alibaba (BABA) is increasingly focusing on the expansion of AI infrastructure and cloud services, funded...

Ionis Pharmaceuticals: A Rare Milestone and the Strategic Shift in Neurology - Experts See 98% Share Price Potential!

The FDA approval for Zanvastro, 19 days before the PDUFA date, opens the door to an untapped market for...

Fuelcell Energy: Price Target of 30 USD Meets Billion-Dollar Order Backlog

The strategic focus on data centers drives the order backlog of Fuelcell Energy (FCEL) to over 3.6 billion...

Fervo Energy Company: 400 MW Contract with Google and Over 150% Upside Potential!

Fervo Energy (FRVO) employs modified drilling techniques for weather-independent, emissions-free geothermal...

Latigo Biotherapeutics

Latigo Biotherapeutics: Guggenheim's buy recommendation with over 100% upside potential draws attention to NaV1.8 inhibitors

Latigo Biotherapeutics (LTGO) focuses on non-opioid analgesics for acute and chronic pain. On September...

Attovia Therapeutics Inc.: Leerink Initiates Coverage on Stock After Successful IPO with Price Target of $52!

Attovia Therapeutics (ATTO) develops complex biologics for immune-mediated diseases using its proprietary...

Iren Ltd.: From Post-Earnings Sell-Off to $90 Target - H.C. Wainwright Sees a Buying Opportunity

Iren Ltd. (IREN) is undergoing a strategic shift from Bitcoin mining to AI cloud infrastructure. The...

Zymeworks Inc.: FDA approval for Ziihera triggers target price increase to 55 USD and milestone payment

The business model of Zymeworks Inc. (ZYME) combines internal research with strategic partners, relieving...

Methode Electronics: Data Center Expansion and E-Mobility as Revenue Drivers - Craig-Hallum Sets Target Price of $30

Craig -Hallum rates Methode Electronics (MEI) on August 25 with a buy recommendation and a target price...

Shattuck Labs: Raymond James sees the DR3 antibody as a growth driver - Expert sees 130% price potential

Raymond James has assigned a "Strong Buy" rating to the stock of Shattuck Labs (STTK) and has set an...

Ultragenyx: The first FDA approval in the gene therapy segment - Experts raise the price target to $103!

The US health authority FDA has granted accelerated approval for the gene therapy Genglycos by Ultragenyx...

Nuvation Bio: Hidden Valuation Reserves in the Precision Oncology Sector?

Nuvation Bio (NUVB) looks at a strong Q2 and liquidity of $661 million. JPMorgan initiated coverage on...

adesso SE: AI contracts worth €73 million bring industry discount into focus - Berenberg sees 121% price potential

Analysts at the private bank Berenberg see a price target of €128 for adesso SE (i.) and point to the...

Eton Pharmaceuticals: 99% Revenue Jump from Rare Diseases and the Path to a 35% Margin

The focus of Eton Pharmaceuticals (ETON) on therapeutics for rare diseases led to a revenue growth of...

AbSci: AI-Based Antibody Development Meets Billion-Dollar Hair Loss Market - H.C. Wainwright Sees 74% Upside Potential

Looking at the top price targets set by analysts, on August 12, AbSci Corp. (ABSI) stands out positively...

Olema Pharmaceuticals: Financial Headwinds Meet Billion-Dollar Market Potential - Experts See Up to 400% Price Potential!

Olema Pharmaceuticals (OLMA) ended the second quarter with cash equivalents amounting to $461.1 million...

Deep Fission: The Challenging Path from 31 Million USD Quarterly Loss to Commercial Scaling - Seaport Sees 178% Price Potential

The business model of Deep Fission (FISN) is based on placing modular pressurized water reactors at...

CoreWeave: Between Margin Pressure and Profit Potential in AI Infrastructure - Deutsche Bank Research Sees 72% Upside Potential

Deutsche Bank has reiterated its rating for CoreWeave (CRWV) on August 7, maintaining a "Buy" recommendation...

Amplitude Inc.: AI Integration as a Catalyst for Double-Digit Growth? - Needham Sees 70% Price Potential!

Amplitude Inc. (AMPL) was able to break out yesterday in response to strong fundamentals and an upward...